Raman Spectroscopy Diagnosis of Kidney Diseases

Launched by ZUNSONG WANG · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose kidney diseases, specifically IgA Nephropathy, Membranous Nephropathy, Diabetic Nephropathy, and Focal Segmental Glomerulosclerosis. Researchers at Qianfoshan Hospital in Shandong Province are collecting blood and urine samples from patients who have been diagnosed with these conditions through kidney biopsies. They will use a special technology called Raman spectroscopy to analyze these samples and identify specific chemical compounds that may help in understanding the diseases better. This study aims to create a non-invasive and efficient tool for diagnosing kidney diseases and predicting how well treatments might work.

To participate in this trial, you need to be 18 years or older and have a confirmed diagnosis of one of the kidney diseases mentioned, without having received certain treatments beforehand. The study is designed for all genders. Participants can expect to provide blood and urine samples, which will be carefully analyzed. It’s important to note that certain health conditions, like severe infections or cancers, may exclude individuals from participating. This research could potentially lead to improved diagnosis and treatment options for kidney disease patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 18 years or older;
• • 2. Patients diagnosed with IgA nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy;
• • 3. Patients who have not received hormone and/or immunosup therapy before the renal biopsy;
• Exclusion Criteria:
• • 1. Presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),/infections (viral hepatitis), drugs or toxins, etc.;
• • 2. Severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09/L);
• • 3. Severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias;
• • 4. Infect diseases: active phase of various types of hepatitis, AIDS, syphilis, etc.;
• • 5. Evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor;
• • 6. Patients with incomplete data or missed diagnosis.